C. difficile

Clostridioides difficile is a bacterium that causes diarrhea and inflammation of the colon.

Quick Answer

What it is

Clostridioides difficile is a bacterium that causes diarrhea and inflammation of the colon.

Key findings

  • Grade C: C. difficile Infection Risk (Lactobacillus acidophilus)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: C. difficile

  • Supplements Studied:0
  • Top Supplement:Lactobacillus acidophilus (C)
0 supps · 0 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Strong Evidence

Primary Stack (Tier 1)

250-500mg twice daily during and after antibiotic treatment

Yeast probiotic that reduces C. difficile recurrence; survives antibiotics; produces anti-toxin protease

30 studies | 4,000 participants
20-50 billion CFU daily (multi-strain formula)

Restore healthy gut microbiome; competitive exclusion of C. difficile; support colonization resistance

40 studies | 8,000 participants

Supporting Stack (Tier 2)

2000-4000 IU daily

Supports immune function; deficiency associated with C. difficile risk and severity

10 studies | 1,000 participants
15-30mg daily

Supports immune function and gut barrier integrity; may reduce infection severity

5 studies | 300 participants
5-10g daily

Supports intestinal barrier function and gut mucosal health

5 studies | 250 participants
5-10g prebiotic fiber daily (introduce gradually)

Feeds beneficial gut bacteria; supports microbiome recovery after antibiotics

10 studies | 600 participants
1-3g daily

Contains immunoglobulins; may help neutralize C. difficile toxins

4 studies | 150 participants

How It Works

Clostridioides difficile (C. diff) is a bacterium that causes severe diarrhea and colitis, primarily in people who have recently taken antibiotics. Antibiotics disrupt the normal gut microbiome, allowing C. diff to overgrow and produce toxins that damage the intestinal lining. Symptoms range from mild diarrhea to severe, life-threatening colitis. Recurrence is common (20-30% after first episode).

CRITICAL: C. difficile infection requires medical treatment. Mild-moderate cases are treated with vancomycin or fidaxomicin antibiotics. Severe cases may require hospitalization, IV fluids, and sometimes surgery for fulminant colitis. Stop the causative antibiotic if possible. These supplements support prevention and recovery but are NOT treatments for active infection. If you have severe diarrhea, fever, abdominal pain, or bloody stool, seek medical care immediately.

PREVENTION IS KEY:

Avoid unnecessary antibiotics
If antibiotics are needed, take probiotics (start same day and continue 2 weeks after)
Good hand hygiene (C. diff spores are NOT killed by alcohol hand sanitizers - use soap and water)
Hospital infection control measures

* Saccharomyces boulardii is a yeast probiotic with the strongest evidence for preventing C. diff. It survives antibiotics (unlike bacterial probiotics) and produces enzymes that break down C. diff toxins. Meta-analyses show significant reduction in C. diff infections.

* Lactobacillus and Bifidobacterium probiotics help restore the normal gut microbiome and provide "colonization resistance" against C. diff.

* Vitamin D deficiency is associated with increased C. diff risk and severity.

* Prebiotics (fiber) feed beneficial bacteria and support microbiome recovery.

* Glutamine supports the gut barrier.

For recurrent C. diff: Fecal microbiota transplant (FMT) is highly effective (>90% cure rate) and increasingly available. Discuss with your gastroenterologist.

Expected timeline: Probiotics should be started with antibiotics and continued for at least 2-4 weeks after. Full microbiome recovery can take months.

Generated from peer-reviewed researchSchema v2.0

Supplements for C. difficile

Sorted by strength of evidence

Detailed Outcomes

C
C. difficile Infection Risk
A review of clinical evidence assessed the use of a specific probiotic combining L. acidophilus with L. casei and L. rhamnosus for primary prevention of C. difficile infections, finding supportive evidence. Preclinical work showed L. acidophilus modulates the virulence of C. difficile in vitro, providing mechanistic support.
3 studies
moderateImproves

Research Citations (20)

Potential benefits of L. acidophilus in dyslipidemic rats
(2021)
PMID: 33731756
Effect of a Probiotic Supplement Containing Lactobacillus Acidophilus and Bifidobacterium Animalis Lactis on Urine Oxalate in Calcium Stone Formers with Hyperoxaluria: A Randomized, Placebo-controlled, Double-blind and In-vitro Trial
(2021)
PMID: 34129232
Preventive Effect of Lactobacillus acidophilus XY27 on DSS-Induced Ulcerative Colitis in Mice
(2020)
PMID: 33376308
Immune enhancing effects of Lactobacillus acidophilus on Newcastle disease vaccination in chickens
(2020)
PMID: 32721773
Lactobacillus acidophilus attenuates toxin production by Vibrio cholerae and shigella dysenteriae following intestinal epithelial cells infection
(2020)
PMID: 33010360
Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence
(2018)
PMID: 29702133
Lactobacillus acidophilus Alleviated Salmonella-Induced Goblet Cells Loss and Colitis by Notch Pathway
(2018)
PMID: 30198100
Lactobacillus acidophilus ameliorates pain and cartilage degradation in experimental osteoarthritis
(2018)
PMID: 30003932
Efficacy of a standardized extract of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) in infantile colic: An open randomized controlled trial
(2017)
PMID: 28665038
Uromodulin-SlpA binding dictates Lactobacillus acidophilus uptake by intestinal epithelial M cells
(2017)
PMID: 28992252

Related Conditions